Potent And Highly Soluble Pegylated Compstatin Peptide

Inhibit complement activation by targeting protein C3, the converging point of all three complement activation pathwaysPossess highly improved aqueous solubility properties and overcome the aggregation limitation for clinical translation of previously known compstatin peptidesPossess significantly improved inhibitory efficacy and retain inhibitory potency, compared to previously known compstatin peptides

None

20180057538

Background

Lack of regulation in complement response is implicated in the pathology of several disorders, such as age-related macular degeneration, paroxysmal nocturnal hemoglobinurea, rare kidney diseases, chronic obstructive pulmonary disease, lupus, rheumatoid arthritis, asthma, adult respiratory distress syndrome, hemolytic anemia, rejection of xenotransplantation, stroke, heart attack, and ischemia reperfusion injuries. Regulating complement activation is important to control inflammation, autoimmune diseases, and infections. The compstatin family of peptides have been shown to be potent inhibitors of complement system activation and are promising candidates to become therapeutics for the treatment of age-related macular degeneration, and other complement-mediated diseases.

Applications

• Therapeutics for age-related macular degeneration (both dry and wet forms)
• Potential therapeutics for other complement system-mediated inflammatory and autoimmune diseases, such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, chronic obstructive pulmonary disease, lupus, rheumatoid arthritis, and ischemia reperfusion injuries

Patent Status

Patent Pending

Related Materials

Mohan RR, Cabrera AP, Harrison RES, Gorham RD Jr, Johnson LV, Ghosh K, Morikis D (2016) Peptide redesign for inhibition of the complement system: targeting age-related macular degeneration. Molecular Vision 22:1280-1290.

Tech ID/UC Case

27122/2017-046-0

Related Cases

2017-046-0

USA